// App-Quantinova.ai

Mo1221 : Adalimumab Maintains Remission for Up to 4 Years in Patients With Ulcerative Colitis

Researchers

Presenter

  • William Sandborn

Principal Investigators

  • Subrata Ghosh

  • Roopal Thakkar

  • Douglas C. Wolf

  • Remo Panaccione

  • Brian G. Feagan

  • Walter Reinisch

  • Anne Robinson

  • Andreas Lazar

  • Martina Kron

  • Bidan Huang

Medical Centers

  • Atlanta Gastroenterology Associates, Atlanta, GA

  • Robarts Reserach Institute, London, ON, Canada

  • University of California, San Diego, La Jolla, CA

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • University of Calgary, Calgary, AB, Canada

  • McMaster University, Hamilton, ON, Canada

Locations

  • United States

  • Canada

Companies

  • AbbVie Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

Outcome

  • N/A

Study Design

  • open label

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved